Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages

  Cunha, Lucas Leite ^a   Morari, Elaine Cristina ^a   Guihen, Ana Carolina Trindade ^a   Razolli, Daniela ^a   Gerhard, Renê ^b   Nonogaki, Suely ^c   Soares, Fernando Augusto ^d   Vassallo, José ^a,d   Ward, Laura Sterian ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; MUCIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; THYROGLOBULIN; THYROTROPIN; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

BONE MARROW CELL; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; MYELOID DERIVED SUPPRESSOR CELL; NODULAR GOITER; TH17 CELL; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ADENOMA; CARCINOMA, PAPILLARY; GOITER; HUMANS; LYMPHOCYTES; MACROPHAGES; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862662743     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0285     Document Type: Letter

References (16)

1. Bertelli DF, Araujo EP, Cesquini M, Stoppa GR, Gasparotto-Contessotto M, Toyama MH, Felix JV, Carvalheira JB, Michelini LC, Chiavegatto S et al. 2006 Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits inositide trisphosphate accumulation in hypothalamus and regulates food intake and body weight. Endocrinology 147 5385-5399. (doi:10.1210/en.2006-0280)
2. Bruland O, Fluge O, Akslen LA, Eiken HG, Lillehaug JR, Varhaug JE & Knappskog PM 2009 Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer 9 425. (doi:10.1186/1471-2407-9-425)
3. Dvorak HF 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 315 1650-1659. (doi:10.1056/NEJM198612253152606)
4. El Demellawy D, Nasr A & Alowami S 2008 Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagnostic Pathology 3 5. (doi:10.1186/1746-1596-3-5)
5. El Demellawy D, Nasr AL, Babay S & Alowami S 2009 Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathology, Research and Practice 205 303-309. (doi:10.1016/j.prp.2008.11.011)
6. Gomez GG, Hickey MJ, Tritz R & Kruse CA 2008 Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors. Gene Therapy & Molecular Biology 12 101-110.
7. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
8. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S & Evers BM 2007 Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. Journal of the American College of Surgeons 204 764-773 discussion 773-775. (doi:10.1016/j.jamcollsurg.2006.12.037)
9. Modi J, Patel A, Terrell R, Tuttle RM & Francis GL 2003 Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. Journal of Clinical Endocrinology and Metabolism 88 4418-4425. (doi:10.1210/jc.2003-030342)
10. Moore A, Medarova Z, Potthast A & Dai G 2004 In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Research 64 1821-1827. (doi:10.1158/0008-5472.CAN-03-3230)
11. Morari EC, Silva JR, Guilhen AC, Cunha LL, Marcello MA, Soares FA, Vassallo J & Ward LS 2010 Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome. Endocrine Pathology 21 242-249. (doi:10.1007/s12022-010-9137-4)
12. Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung CF, Wu TC & Kim TW 2009 Activation of Akt as a mechanism for tumor immune evasion. Molecular Therapy 17 439-447. (doi:10.1038/mt.2008.255)
13. Shaha AR 2007 TNM classification of thyroid carcinoma. World Journal of Surgery 31 879-887. (doi:10.1007/s00268-006-0864-0)
14. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF & Peng G 2010 Tumor microenvironments direct the recruitment and expansion of human Th17 cells. Journal of Immunology 184 1630-1641. (doi:10.4049/jimmunol.0902813)
15. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC et al. 2005 Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104 2084-2091. (doi:10.1002/cncr.21470)
16. Zhou G & Levitsky HI 2007 Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. Journal of Immunology 178 2155-2162. (Pubitemid 46233413)